Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
暂无分享,去创建一个
R. Larson | M. Baccarani | D. Marin | H. Kantarjian | J. Cortes | F. Giles | T. Fischer | T. Facon | S. Goldberg | N. Gallagher | R. Bhatia | D-W. Kim | G. Rosti | M. Jagasia | U. Dünzinger | E. Abruzzese | A. Bosly | J. Cortes | Y. Shou | G. Kam | W. Mendrek | M. Mueller | F. Mahon | T. Fischer | D. Kim | Dong-Kee Kim | F. Mahon
[1] D. White,et al. Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells , 2010, Leukemia.
[2] J. Goldman. Chronic myeloid leukemia: reversing the chronic phase. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Radich,et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.
[4] J. Melo,et al. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy , 2010, Leukemia.
[5] H. Kantarjian,et al. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history , 2010, Leukemia.
[6] J. Radich,et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] F. Giles,et al. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia , 2009, Leukemia.
[8] J. Melo,et al. Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.
[9] M. Deininger,et al. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.
[10] Susan O'Brien,et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. , 2007, Blood.